Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancer.

Seminars in oncology - 1 Feb 2025

Pala Laura, De Pas Tommaso, Cocorocchio Emilia, Catania Chiara, Ceresoli Giovanni, Laszlo Daniele, Zattarin Emma, Rossi Giovanna, Conforti Fabio

Abstract excerpt

OBJECTIVES: We previously showed that men with melanoma harboring BRAF mutations had significantly lower benefit from targeted therapy as compared with women Here we explored the hypothesis that such gender-based dimorphism in the efficacy of BRAF-pathway blockade extends to other tumor histotypes carrying pathogenic BRAF-mutations. METHODS: We retrospectively analyzed data from a cohort of patients with advanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Sex Factors

Source

Identifiers

PMID: 39627078
DOI: 10.1053/j.seminoncol.2024.10.004

Genes

BRAF
EGFR
RNF43

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancer.PMID 39627078Read ↗

Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI.Semantic proximity Read ↗

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapySemantic proximity Read ↗

BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis.Semantic proximity Read ↗

The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis.Semantic proximity Read ↗

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.Semantic proximity Read ↗

Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).Semantic proximity Read ↗

The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference.Semantic proximity Read ↗

Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy.Semantic proximity Read ↗

Differences in gene mutations according to gender among patients with colorectal cancer.Semantic proximity Read ↗

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.